Nick Fox

Professor and Head of Department

UCL Institute of Neurology, University College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Nick Fox is the Head of Department at the UCL Institute of Neurology, University College London, UK. His research primarily focuses on Alzheimer's disease, with recent articles addressing cerebrovascular pathology, biological correlates of disease progression, and the effects of anti-amyloid therapies. Additionally, he explores the intersection of climate change and neurological disorders, as well as genetic testing in dementia. His work contributes to enhancing understanding and improving interventions in neurodegenerative diseases.

Articles (20)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Lei Liu

Assistant Professor of Neurology

Harvard Medical School

UNITED STATES

Nick Fox

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia

Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer's disease

Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removalrelated pseudo-atrophy

Climate change and disorders of the nervous system

Data-driven modelling of neurodegenerative disease progression: thinking outside the black box

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Genetic testing in dementia

Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease

Neuroimaging, clinical and life course correlates of normal-appearing white matter integrity in 70-year-olds

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease

Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease

Preparing for disease-modifying therapies in Alzheimer's disease.

Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [<sup>18</sup>F]flortaucipir study.

Operationalizing the centiloid scale for [<sup>18</sup>F]florbetapir PET studies on PET/MRI.

Acceptability and feasibility of plasma phosphorylated-tau181 in two memory services.

Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.

Collaborators (19)

Lei Liu

anna barnes

William Klunk

Michael Schöll

Alisha Daniels

Naaheed Mukadam

Jemma Hazan

Gerald Reischl

Sarah-Naomi James

Kazushi Suzuki

Erik Johnson

Charlene Supnet

Brian Gordon

William Coath

M. Jorge Cardoso

Carlos Cruchaga

Qing Wang

Nelly Joseph-Mathurin

Clifford Jack

Make your next move.